KCTD14 Activators
KCTD14 initiate their effects through various signaling pathways that lead to the phosphorylation and activation of the protein. Forskolin, Isoproterenol, PGE2, IBMX, Dibutyryl-cAMP, 8-Br-cAMP, Rolipram, Epinephrine, and FSK share a common mechanism of raising intracellular cyclic AMP (cAMP) levels, albeit through different modes of action. Forskolin and FSK, being direct stimulators of adenylate cyclase, increase cAMP levels that activate protein kinase A (PKA). Isoproterenol and Epinephrine, as beta-adrenergic agonists, and PGE2, through its interaction with EP receptors, also activate adenylate cyclase, subsequently raising cAMP levels and activating PKA. IBMX and Rolipram extend the increase in cAMP by inhibiting phosphodiesterases, enzymes responsible for cAMP breakdown, thus sustaining PKA activation. Dibutyryl-cAMP and 8-Br-cAMP, as cAMP analogs, bypass the cell surface receptors and directly activate PKA. The activation of PKA triggers a cascade of phosphorylation events that can lead to the activation of KCTD14.
Anisomycin and Phorbol 12-myristate 13-acetate (PMA) activate KCTD14 through different pathways. Anisomycin functions by inhibiting protein synthesis and activating stress-activated protein kinases such as JNK, which can phosphorylate various substrates including KCTD14. PMA, on the other hand, is a potent activator of protein kinase C (PKC). PKC phosphorylates a wide array of proteins, and this action can lead to the modification of KCTD14 or its associated signaling proteins. Sp-5,6-DCl-cBIMPS, being a selective activator of PKA, directly enhances PKA activity, which, in turn, can lead to the phosphorylation and activation of KCTD14. Each of these chemical activators, through their unique interactions with cellular enzymes and signaling pathways, contribute to the regulation and activation of KCTD14.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, leads to the activation of the G-protein coupled receptor which then activates adenylate cyclase, increasing intracellular cAMP levels. The rise in cAMP activates PKA, which can lead to the phosphorylation and subsequent activation of KCTD14. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 binds to its G-protein coupled receptors (EP receptors), leading to increased cAMP production via adenylate cyclase activation. The cAMP then activates PKA, which could phosphorylate KCTD14, leading to activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs), enzymes that break down cAMP. By preventing cAMP degradation, IBMX effectively increases cAMP levels, leading to activation of PKA. PKA can then phosphorylate and possibly activate KCTD14. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is a cell-permeable cAMP analog that directly activates cAMP-dependent pathways by mimicking the action of cAMP. This activation of cAMP-dependent pathways, such as PKA, can lead to the phosphorylation and activation of proteins, including KCTD14. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cell-permeable cAMP analog that activates cAMP-dependent protein kinases (PKA). Activation of PKA can result in phosphorylation and activation of KCTD14 through downstream signaling cascades. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to increased intracellular cAMP levels. As a result, PKA becomes activated, which may phosphorylate and activate KCTD14. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine engages with beta-adrenergic receptors, leading to the activation of adenylate cyclase and an increase in cAMP. This rise in cAMP levels activates PKA, which can lead to the phosphorylation and potential activation of KCTD14. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can activate stress-activated protein kinases (SAPKs), such as JNK. JNK activation can lead to phosphorylation of various substrates, potentially including KCTD14, leading to its activation as part of a cellular stress response. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates protein kinase C (PKC). PKC can phosphorylate a wide range of proteins and could contribute to the activation of KCTD14 by phosphorylating it or members of its signaling pathway. | ||||||